Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is a promising investment with a positive outlook, as the company's ABC platform and investigational medicines have the potential to greatly improve treatment for retinal diseases. With several upcoming catalysts in 2026, including the release of Phase 3 trial data for tarcocimab and KSI-501, we believe the company has the potential for significant growth. Our valuation and risks analysis has resulted in a Buy rating and increased price target, factoring in the potential success of the ABC pipeline, the company's execution history, and positive feedback from key opinion leaders. However, there are risks to consider, such as the failure to secure capital resources and the potential for underperformance of developmental candidates.

Bears say

Kodiak Sciences is reporting positive results for its investigational drug, tarcocimab tedromer, in diabetic retinopathy which validates their reformulated ABC platform design. However, the company's other investigational medicine, KSI-501, also being developed on the ABC platform, only has a 35-60% chance of success in wet AMD and DR. Overall, the positive tarcocimab update may contribute to potential future success, but other factors such as the limited applicability of the ABC platform and the high-risk nature of drug development could still hinder Kodiak's long-term prospects and justify a negative outlook.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.